Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. It develops and commercializes the senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company was founded by Konstantinos Alataris in March 2006 and is headquartered in Redwood City, CA.
相关临床试验
10
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
30.0%
已完成
5
50.0%
终止
1
10.0%
Unknown
1
10.0%
暂无批准数据
- Nevro's HFX iQ spinal cord stimulation (SCS) system, leveraging AI and high-frequency therapy, has secured CE mark in Europe for personalized pain relief. - The HFX iQ system incorporates an implantable pulse generator (IPG), trial stimulator, and app, enabling real-time adjustments based on patient input. - Built upon 20 million data points and 80,000 implanted patients, the HFX algorithm selects programs tailored to individual pain relief needs. - Nevro plans a phased launch in select European countries starting in Q1 2025, expanding access to this AI-powered SCS therapy.
- Nevro's HFX iQ with AdaptivAI, an AI-driven spinal cord stimulation system, has gained FDA approval for chronic pain management. - HFX AdaptivAI leverages AI and patient data to personalize pain relief, optimizing therapy and potentially reducing device charging frequency. - The system offers real-time insights and remote monitoring, enhancing patient-clinician interactions and enabling proactive pain management. - Nevro plans a full market release in the U.S. in Q4 2024, expanding access to this innovative pain relief technology.
